Literature DB >> 16870521

Development of vaccines against influenza H5.

Iain Stephenson, Ian Gust, Yuri Pervikov, Marie Paule Kieny.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16870521     DOI： 10.1016/S1473-3099(06)70528-X

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  8 in total

Review 1.  The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-06-01       Impact factor: 3.402

Review 2.  Advances in novel influenza vaccines: a patent review.

Authors:  Jae-Min Song
Journal:  J Microbiol       Date:  2016-05-27       Impact factor: 3.422

Review 3.  Avian influenza virus (H5N1): a threat to human health.

Authors:  J S Malik Peiris; Menno D de Jong; Yi Guan
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

4.  Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge.

Authors:  Jyothi K Mallajosyula; Ernie Hiatt; Steve Hume; Ashley Johnson; Trushar Jeevan; Rachel Chikwamba; Gregory P Pogue; Barry Bratcher; Hugh Haydon; Richard J Webby; Alison A McCormick
Journal:  Hum Vaccin Immunother       Date:  2013-12-30       Impact factor: 3.452

5.  Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults.

Authors:  Benjamin Lasko; Dennis Reich; Anuradha Madan; François Roman; Ping Li; David Vaughn
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

6.  An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults.

Authors:  Paul Gillard; Adrian Caplanusi; Markus Knuf; François Roman; Karl Walravens; Philippe Moris; Mamadou Dramé; Tino F Schwarz
Journal:  Influenza Other Respir Viruses       Date:  2012-03-09       Impact factor: 4.380

7.  Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines.

Authors:  Tila Khan; Connie L Heffron; Kevin P High; Paul C Roberts
Journal:  Virol J       Date:  2014-05-03       Impact factor: 4.099

8.  Optimized clade 2.3.2.1c H5N1 recombinant-vaccine strains against highly pathogenic avian influenza.

Authors:  Jin-Wook Jang; Chung-Young Lee; Il-Hwan Kim; Jun-Gu Choi; Youn-Jeong Lee; Seong-Su Yuk; Ji-Ho Lee; Chang-Seon Song; Jae-Hong Kim; Hyuk-Joon Kwon
Journal:  J Vet Sci       Date:  2017-08-31       Impact factor: 1.672
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.